| Citation: |
MENG Wenjing, ZHANG Jibo, LI Shufen, TONG Zhongsheng. Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2018, 45(2): 86-90. DOI: 10.3971/j.issn.1000-8578.2018.17.0975
|
To analyze the cardiac safety of trastuzumab on HER2 positive breast cancer patients.
Trastuzumab was administrated every three weeks in 185 patients with HER2 positive breast cancer. The initial dose was 8 mg/kg, and the subsequent dose was 6 mg/kg, for 4-36 cycles. The cardiotoxicity of these patients was analyzed.
The median treatment was 17 cycles in Her-2 positive breast cancer patients who received trastuzumab. Left ventricular ejection fraction (LVEF) level dropped in 88 cases (47.6%) after trastuzumab treatment; 74 patients (40.0%) occurred valvular regurgitation (new+ aggravation); 16 patients (8.0%) occurred the reduction of diastolic function of left ventricle; 88 patients (47.6%) experienced cardiotoxicity, among which 83 patients experienced gradeⅠcardiotoxicity and five patients experienced grade Ⅱ cardiotoxicity, no patient experienced grade Ⅲ cardiotoxicity.
The treatment of trastuzumab on Chinese patients with HER2 positive breast cancer shows a satisfactory cardiac safety. However, the potential cardiotoxicity of trastuzumab should be carefully monitored during therapy.
| [1] |
Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29. doi: 10.3322/caac.21208
|
| [2] |
Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Ann Oncol, 2011, 22(8): 1736-47. doi: 10.1093/annonc/mdr304
|
| [3] |
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol, 2013, 24(9): 2206-23. doi: 10.1093/annonc/mdt303
|
| [4] |
Mignot F, Ajgal Z, Xu H, et al. Concurrent administration of anti-HER2 therapy and radiotherapy: Systematic review[J]. Radiother Oncol, 2017, 124(2): 190-9. doi: 10.1016/j.radonc.2017.07.006
|
| [5] |
Florido R, Smith KL, Cuomo KK, et al. Cardiotoxicity from human epidermal growth factor receptor-2 (HER2) targeted therapies[J]. J Am Heart Assoc, 2017, 6(9): pii: e006915. doi: 10.1161/JAHA.117.006915
|
| [6] |
Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer[J]. Curr Opin Cell Biol, 2009, 21(2): 177-84. doi: 10.1016/j.ceb.2008.12.010
|
| [7] |
Aitelhaj M, Lkhouyaali S, Rais G, et al. Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients[J]. BMC Res Notes, 2013, 6: 339. doi: 10.1186/1756-0500-6-339
|
| [8] |
Demonty G, Bernard-Marty C, Puglisi F, et al. Progress and new standards of care in the management of HER-2 positive breast cancer[J]. Eur J Cancer, 2007, 43(3): 497-509. doi: 10.1016/j.ejca.2006.10.020
|
| [9] |
中国抗癌协会乳腺癌专业委员会. Her-2阳性乳腺癌临床诊疗专家共识[J].中国癌症杂志, 2012, 22(4): 314-8. http://news.medlive.cn/cancer/info-progress/show-110864_53.html
Committee on Breast Cancer of Chinese Cancer Society. Expert consensus on clinical diagnosis and treatment of Her-2 positive breast cancer[J]. Zhongguo Ai Zheng Za Zhi, 2012, 22(4): 314-8. http://news.medlive.cn/cancer/info-progress/show-110864_53.html
|
| [10] |
Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China[J]. Lancet Oncol, 2014, 15(7): e279-89. doi: 10.1016/S1470-2045(13)70567-9
|
| [11] |
Sun Y, Li T, Zhang Y, et al. Evaluation of Left Ventricular Ejection Fractions in Breast Cancer Patients Undergoing Long-Term Trastuzumab Treatment[J]. Med Sci Monit, 2016, 22: 5035-40. doi: 10.12659/MSM.898807
|
| [12] |
Jankowitz RC, Abraham J, Tan AR, et al. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2 positive breast cancer: an NSABP Foundation Research Program phase Ⅰ study[J]. Cancer Chemother Pharmacol, 2013, 72(6): 1205-12. doi: 10.1007/s00280-013-2262-2
|
| [13] |
da Fonseca LG, de Melo Gagliato D, Takahashi TK, et al. Cardiac safety of (neo)adjuvant trastuzumab in the community setting: a single-center experience[J]. Breast Care (Basel), 2014, 9(4): 255-60. http://www.ncbi.nlm.nih.gov/pubmed/25404884
|
| [14] |
Nemeth BT, Varga ZV, Wu WJ, et al. Trastuzumab cardiotoxicity: from clinical trials to experimental studies[J]. Br J Pharmacol, 2016, 7. https://www.researchgate.net/publication/308946285_Trastuzumab_cardiotoxicity_From_clinical_trials_to_experimental_studies
|
| [15] |
Florido R, Smith KL, Cuomo KK, et al. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies[J]. J Am Heart Assoc, 2017, 6(9): pii: e006915. doi: 10.1161/JAHA.117.006915
|
| [16] |
Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31[J]. J Clin Oncol, 2011, 29 (25): 3366-73. doi: 10.1200/JCO.2011.35.0868
|
| [17] |
Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer[J]. J Clin Oncol, 2012, 30(31): 3792-9. doi: 10.1200/JCO.2011.40.0010
|
| [18] |
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. N Engl J Med, 2011, 365(14): 1273-83. doi: 10.1056/NEJMoa0910383
|
| [19] |
Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J]. J Clin Oncol, 2014, 32(33): 3744-52. doi: 10.1200/JCO.2014.55.5730
|
| [20] |
Jones SE, Collea R, Paul D, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study[J]. Lancet Oncol, 2013, 14(11): 1121-8. doi: 10.1016/S1470-2045(13)70384-X
|
| [21] |
Gligorov J, Ataseven B, Verrill M, et al. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase Ⅲ study's primary analysis of 2573 patients[J]. Eur J Cancer, 2017, 82: 237-46. doi: 10.1016/j.ejca.2017.05.010
|
| [22] |
Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial[J]. Lancet, 2007, 369(9555): 29-36. doi: 10.1016/S0140-6736(07)60028-2
|
| 1. |
莫艳秀，姚飞虹，刘峻彤，胡紫昂，李木兰. SP600125对人宫颈癌HeLa细胞增殖和侵袭的影响. 肿瘤防治研究. 2022(04): 304-313 .
 本站查看
| |
| 2. |
赵永，黄萍，郭子文，汪琼. 基于加权基因共表达网络分析慢性阻塞性肺疾病的差异基因及信号通路. 华南国防医学杂志. 2022(12): 959-966 .
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: